A Study on Rheumatoid Arthritis Patients Treated With Rituximab

Hoffmann-La Roche81 enrolled

Overview

The purpose of the study is to obtain an overall picture of rituximab treatments and treatment responses in RA patients.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Rheumatoid Arthritis

Interventions

RituximabDRUG

This is an observational study. Patients with rheumatoid arthritis and having received treatment previously will be assessed for the treatment responses.

Eligibility

Sex: ALL

Medical Language ↔ Plain English

Inclusion Criteria: * Rheumatoid arthritis (RA) patients treated with rituximab in Finland Exclusion Criteria: * Not applicable

Locations (5)

Unnamed facility

Helsinki, Finland

Unnamed facility

Jyväskylä, Finland

Unnamed facility

Lahti, Finland

Unnamed facility

Tampere, Finland

Unnamed facility

Turku, Finland

Outcomes

Primary Outcomes

Information on previous RA treatments

Time frame: 3 months

Information on rituximab treatment responses

Time frame: 3 months

Information on concomitant medications

Time frame: 3 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.